I have always thought the NEU strategy was (can’t remember what lead me to this) that Trofenitide would be sold as a stand alone drug, and that enough work would be done on NNZ-2591 to realize optimum value, with an ultimate sale of the drug in total.
Ill admit that things seem to have moved from there - to NEU possibly going the whole way alone / but the bottom line is that if a sale was to materialise for NEU I never thought that Trofenitide would be part of it.
So the RoW rights doesn’t impact this approach.
I have always thought the NEU strategy was (can’t remember what...
-
- There are more pages in this discussion • 622 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |